BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

SCYNEXIS, Inc. Wants to Raise $25 Million by May


2/28/2012 8:37:37 AM

Triangle Business Journal by Lauren K. Ohnesorge, Staff Writer

Scynexis Inc. has raised more than $11 million out of a $25 million goal in its latest fundraiser, according to CEO Yves J. Ribeill.

“It’s going very well,” says Ribeill, who expects to have completed the $25 million round by May.

The money will help the company fund studies for a proposed hepatitis C drug, which currently is in the middle of phase two clinical trials. Ribeill hopes to start phase three trials in 2013. The company could seek FDA approval in 2015 or 2016, provided everything goes as planned.

Once phase two concludes, Scynexis will start looking for a partnering company to push the product through the final stages and commercialization, he said.

Ribeill hopes the drug, intended to be taken orally, will completely “get rid of the virus” in 12 weeks or less.

The company has raised more than $50 million since 2002. Headquartered in Durham, Scynexis was selected by Morria Biopharmaceuticals earlier this month as its chemical development and production partner for an allergic rhinitis drug.

Back in December, Scynexis had raised $5.5 million of the round, which was then billed as a $15 million stock and debt offering.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->